Skip to main content
. 2018 Dec 19;18:1271. doi: 10.1186/s12885-018-5157-0

Fig. 3.

Fig. 3

Kaplan–Meier curves for overall survival for axitinib versus cabozantinib: (a) base-case analysis; (b) sensitivity analysis. aHR, adjusted hazard ratio; CI, confidence interval; ESS, effective sample size; MAIC, matching-adjusted indirect treatment comparison; OS, overall survival